2030 Immune Response Vaccine 
Drug Discovery World
MAY 6, 2024
billion) Healthcare Innovation 2030 project, with ambitious plans to turn France into the European leader in health innovation by 2030. Since the launch of Healthcare Innovation 2030, investment has continued apace in the region. billion ($7.9 Biotechs such as ourselves and Owkin are leveraging artificial intelligence.”
Drug Discovery World
APRIL 12, 2023
In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 2030 1. Dr Paul Burton, the Chief Medical Officer of Moderna, told the Guardian: “We will have that vaccine and it will be highly effective, and it will save many hundreds of thousands, if not millions of lives.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 11, 2021
Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi ® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers.
Drug Discovery World
FEBRUARY 15, 2023
Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.
Drug Discovery World
MAY 30, 2023
Very recent data from Moderna’s and BioNTech’s personalised vaccines in combination with ICIs in melanoma and pancreatic cancer respectively have shown dramatic improvements when given as part of a triple combination (vaccine plus ICI and chemo/radiotherapy).
PerkinElmer
JANUARY 25, 2023
This should tell us that further development of new and existing diagnostic tools to understand immune response at the cellular level will be worthwhile in 2023 and beyond, not only for long COVID, but for other conditions too. Big, bold commitments such as these will hopefully continue in the year ahead.
The Pharma Data
FEBRUARY 8, 2021
Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.
Expert insights. Personalized for you.
147 
Let's personalize your content